Abstract
Despite recent advances in allogeneic hematopoietic stem cell transplantation (AHSCT), the outcome of patients who have acute myeloid leukemia (AML) with a complex karyotype (CK) remains poor. The objective of this study was to identify prognostic factors associated with post-transplantation survival in a large cohort of patients with CK AML. In total, data on 1342 consecutively patients who underwent transplantation for CK (≥3 chromosomal abnormalities) AML were provided by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and from the University of Texas MD Anderson Cancer Center database were included in the analysis. The median patient age was 52 years. The donors were human leukocyte antigen-matched related donors (N = 749), matched unrelated donors (N = 513), and mismatched unrelated donors (N = 80). Relapse was the main cause of treatment failure. Overall, 51% of patients relapsed, 17.6% died of treatment-related mortality, and 31.3% survived leukemia-free. In multivariate analysis, the factors associated with an increased risk of relapse were age (>40 years; hazard ratio [HR], 1.1 per 10 years; P = .02), secondary AML (HR, 1.35; P = .01), active disease at transplantation (HR,...Continue Reading
References
Jul 15, 1989·Cancer Genetics and Cytogenetics·D C ArthurG W Dewald
Sep 1, 1989·British Journal of Haematology·P FenauxF Bauters
Mar 1, 1984·Cancer Genetics and Cytogenetics·C D BloomfieldA de la Chapelle
Jan 1, 1995·Lifetime Data Analysis·P Hougaard
Jul 9, 1999·Statistics in Medicine·P K AndersenM J Zhang
Feb 13, 2001·British Journal of Haematology·C SchochUNKNOWN German AML Cooperative Study Group
Jun 22, 2001·Leukemia·G VisaniS Tura
Oct 24, 2002·Blood·John C ByrdUNKNOWN Cancer and Leukemia Group B (CALGB 8461)
Sep 30, 2005·Leukemia·M AoudjhaneUNKNOWN Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)
Jun 11, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel WeisdorfJohn Klein
Jun 11, 2009·JAMA : the Journal of the American Medical Association·John KorethCorey Cutler
Nov 3, 2009·Blood·Hartmut DöhnerUNKNOWN European LeukemiaNet
Apr 14, 2010·Blood·David GrimwadeUNKNOWN National Cancer Research Institute Adult Leukaemia Working Group
Jun 18, 2011·Blood·Min FangFrederick R Appelbaum
Jan 28, 2014·Haematologica·Heesun J RogersEric D Hsi
Apr 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart L ScottMitchell E Horwitz
Citations
Feb 12, 2019·Current Treatment Options in Oncology·Yahya DaneshbodDaniel A Arber
Dec 7, 2018·Hematology·Laura C Michaelis
Feb 6, 2020·American Journal of Hematology·Cole Sterling, Jonathan Webster
May 12, 2020·American Journal of Hematology·Michael ByrneMichael Savona
May 16, 2019·Bone Marrow Transplantation·Thierry GuillaumeMohamad Mohty
Mar 9, 2019·Leukemia·Jonathan CanaaniArnon Nagler
Sep 19, 2020·American Journal of Hematology·Monica PoianiMohamad Mohty
Oct 21, 2020·Bone Marrow Transplantation·Luxin YangYi Luo
Jul 28, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Eduardo Rodríguez-ArbolíMohamad Mohty
Nov 18, 2020·Leukemia·Ashkan EmadiRena G Lapidus
Mar 2, 2021·Blood Advances·Antonio PieriniAndrea Velardi
Jul 28, 2021·Leukemia·Stefan O CiureaRichard E Champlin
Aug 21, 2021·Frontiers in Immunology·Roberto LimongelloAntonio Pierini
Sep 3, 2021·Bone Marrow Transplantation·Brian PhamMehrdad Abedi
Oct 15, 2021·Frontiers in Oncology·Tongtong ZhangYang Xu